{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:24:29Z","timestamp":1789557869376,"version":"build-2803163510"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1097\/ftd.0b013e3181dda54f","type":"journal-article","created":{"date-parts":[[2010,4,29]],"date-time":"2010-04-29T09:18:05Z","timestamp":1272532685000},"page":"282-288","source":"Crossref","is-referenced-by-count":28,"title":["Tigecycline: A Review of Properties, Applications, and Analytical Methods"],"prefix":"10.1097","volume":"32","author":[{"given":"Luc\u00e9lia Magalh\u00e3es","family":"da Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9rida Regina","family":"Nunes Salgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-10-20210129","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1046\/j.1469-0691.2000.00107.x","article-title":"Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs).","volume":"6","author":"Paterson","year":"2000","journal-title":"Clin Microbiol Infect"},{"key":"R2-10-20210129","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1128\/AAC.45.6.1721-1729.2001","article-title":"Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995.","volume":"45","author":"Doern","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"R3-10-20210129","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.clinthera.2005.01.007","article-title":"Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant Gram-positive organisms.","volume":"27","author":"Garrison","year":"2005","journal-title":"Clin Ther"},{"issue":"Suppl 4","key":"R4-10-20210129","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1086\/500663","article-title":"Extended-spectrum beta-lactamases and clinical outcomes: current data.","volume":"42","author":"Ramphal","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"Suppl A","key":"R5-10-20210129","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0195-6701(01)90029-5","article-title":"Antimicrobial susceptibility of Gram-positive bacteria: whats current, whats anticipated?","volume":"49","author":"Johnson","year":"2001","journal-title":"J Hosp Infect"},{"key":"R6-10-20210129","doi-asserted-by":"crossref","first-page":"S397","DOI":"10.1378\/chest.119.2_suppl.397S","article-title":"Resistance patterns among nosocomial pathogens: trends over the past few years.","volume":"119","author":"Jones","year":"2001","journal-title":"Chest"},{"key":"R7-10-20210129","doi-asserted-by":"crossref","first-page":"S122","DOI":"10.1038\/nm1145","article-title":"Antibacterial resistance worldwide: causes, challenges and responses.","volume":"10","author":"Levy","year":"2004","journal-title":"Nat Med"},{"key":"R8-10-20210129","doi-asserted-by":"crossref","first-page":"65","DOI":"10.4103\/0022-3859.48443","article-title":"Tigecycline.","volume":"55","author":"Bhattacharya","year":"2009","journal-title":"J Postgrad Med"},{"key":"R9-10-20210129","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1471-4892(01)00081-9","article-title":"Glycylcyclines: third-generation tetracycline antibiotics.","volume":"1","author":"Chopra","year":"2001","journal-title":"Curr Opin Pharmacol"},{"key":"R10-10-20210129","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1124\/dmd.107.015735","article-title":"Metabolism, excretion, and pharmacokinetics of [14C] tigecycline, a first-in-class glycylcycline antibiotic, after intravenous infusion to healthy male subjects.","volume":"35","author":"Hoffmann","year":"2007","journal-title":"Drug Metab Dispos"},{"issue":"Suppl 5","key":"R11-10-20210129","doi-asserted-by":"crossref","first-page":"S315","DOI":"10.1086\/431673","article-title":"In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections.","volume":"41","author":"Bradford","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R13-10-20210129","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.clinthera.2006.08.011","article-title":"Tigecycline: a glycylcycline antimicrobial agent.","volume":"28","author":"Doan","year":"2006","journal-title":"Clin Ther"},{"key":"R14-10-20210129","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1093\/jac\/dkh125","article-title":"Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-direct Fe2+ cleavage of 16S rRNA.","volume":"53","author":"Bauer","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"R15-10-20210129","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2165\/00003495-200464010-00005","article-title":"The glycylcyclines: a comparative review with the tetracyclines.","volume":"64","author":"Zhanel","year":"2004","journal-title":"Drugs"},{"key":"R16-10-20210129","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/jac\/dki291","article-title":"Tigecycline: what is it, and where should it be used?","volume":"56","author":"Livermore","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"R17-10-20210129","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1093\/jac\/dki248","article-title":"Tigecycline.","volume":"56","author":"Pankey","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"R18-10-20210129","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1001\/archinte.168.20.2254","article-title":"Trends in antibacterial use in US academic health centers: 2002 to 2006.","volume":"168","author":"Pakyz","year":"2008","journal-title":"Arch Intern Med"},{"key":"R19-10-20210129","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1128\/AAC.40.9.2226","article-title":"Glycylcyclines bind to the high affinity tetracycline ribosomal binding site and evade Tet (M)- and Tet(O)-mediated ribosomal protection.","volume":"40","author":"Bergeron","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"R20-10-20210129","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1368-7646(02)00051-1","article-title":"New developments in tetracycline antibiotics: glycylcyclines and tetracyclines efflux pump inhibitors.","volume":"5","author":"Chopra","year":"2002","journal-title":"Drug Resist Updat"},{"key":"R21-10-20210129","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1111\/j.1742-1241.2006.01188.x","article-title":"Tigecycline: a new glycylcycline antimicrobial.","volume":"60","author":"Townsend","year":"2006","journal-title":"Int J Clin Pract"},{"key":"R22-10-20210129","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.2146\/ajhp050487","article-title":"Tigecycline: a new glycylcycline antimicrobial agent.","volume":"63","author":"Kasbekar","year":"2006","journal-title":"Am J Health Syst Pharm"},{"key":"R23-10-20210129","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/jac\/dkl403","article-title":"Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose.","volume":"58","author":"Rodvold","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"R24-10-20210129","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1128\/AAC.49.4.1629-1632.2005","article-title":"Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations.","volume":"49","author":"Sun","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 5","key":"R25-10-20210129","doi-asserted-by":"crossref","first-page":"S333","DOI":"10.1086\/431674","article-title":"The pharmacokinetic and pharmacodynamic profile of tigecycline.","volume":"41","author":"Meagher","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R26-10-20210129","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.diagmicrobio.2005.05.006","article-title":"Pharmacokinetic\/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent.","volume":"52","author":"Meagher","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"Suppl 1","key":"R27-10-20210129","doi-asserted-by":"crossref","first-page":"i11","DOI":"10.1093\/jac\/dkn242","article-title":"Tigecycline pharmacokinetic\/pharmacodynamic update.","volume":"62","author":"MacGowan","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"R28-10-20210129","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S0149-2918(04)90070-7","article-title":"Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients.","volume":"26","author":"Postier","year":"2004","journal-title":"Clin Ther"},{"key":"R29-10-20210129","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0732-8893(99)00092-9","article-title":"Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates.","volume":"36","author":"Gales","year":"2000","journal-title":"Diagn Microbiol Infect Dis"},{"key":"R30-10-20210129","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1128\/AAC.44.8.2225-2229.2000","article-title":"In vitro activities of the glycylcycline GAR-936 against Gram positive bacteria.","volume":"44","author":"Boucher","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"R31-10-20210129","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0732-8893(01)00269-3","article-title":"In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant Gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases.","volume":"40","author":"Biedenbach","year":"2001","journal-title":"Diagn Microbiol Infect Dis"},{"key":"R32-10-20210129","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1128\/AAC.49.9.3903-3909.2005","article-title":"Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing reagent Oxyrase to standardize the test method.","volume":"49","author":"Bradford","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"R33-10-20210129","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1086\/505494","article-title":"Tigecycline: a critical analysis.","volume":"43","author":"Stein","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"Suppl 5","key":"R34-10-20210129","doi-asserted-by":"crossref","first-page":"S303","DOI":"10.1086\/431672","article-title":"Tigecycline a new glycylcycline for treatment of serious infections.","volume":"41","author":"Noskin","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R35-10-20210129","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0732-8893(00)00193-0","article-title":"In vitro activity of GAR-936 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae.","volume":"38","author":"Patel","year":"2000","journal-title":"Diagn Microbiol Infect Dis"},{"key":"R36-10-20210129","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1128\/JCM.00637-08","article-title":"In vitro activity of tigecycline against Gram-positive and Gram-negative pathogens as evaluated by broth microdilution and etest.","volume":"46","author":"Pillar","year":"2008","journal-title":"J Clin Microbiol"},{"key":"R37-10-20210129","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/jac\/dki477","article-title":"In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis.","volume":"57","author":"Petersen","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"R38-10-20210129","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1128\/AAC.50.4.1298-1303.2006","article-title":"Impact of Enterococcus faecalis on the bactericidal activities of arbekacin, daptomycin, linezolid, and tigecycline against methicillin-resistant Staphylococcus aureus in a mixed-pathogen pharmacodynamic model.","volume":"50","author":"Laplante","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 3","key":"R39-10-20210129","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/S0924-8579(09)70550-3","article-title":"The tide of antimicrobial resistance and selection.","volume":"34","author":"Wilcox","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"R40-10-20210129","doi-asserted-by":"crossref","first-page":"4658","DOI":"10.1128\/AAC.49.11.4658-4666.2005","article-title":"Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam.","volume":"49","author":"Breedt","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"R41-10-20210129","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ijid.2005.05.003","article-title":"Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: results from a phase 3, randomized, double-blind trial.","volume":"9","author":"Sacchidanand","year":"2005","journal-title":"Int J Infect Dis"},{"issue":"Suppl 5","key":"R42-10-20210129","doi-asserted-by":"crossref","first-page":"S341","DOI":"10.1086\/431675","article-title":"The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam.","volume":"41","author":"Ellis-Grosse","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R43-10-20210129","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ijsu.2005.03.011","article-title":"Tigecycline is efficacious in the treatment of complicated intra-abdominal infections.","volume":"3","author":"Fomin","year":"2005","journal-title":"Int J Surg"},{"key":"R44-10-20210129","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1471-2334-5-88","article-title":"A multicenter trial of the efficacy and safety of tigecycline versus imipenem\/cilastatin in patients with complicated intra-abdominal infections.","volume":"5","author":"Oliva","year":"2005","journal-title":"BMC Infect Dis"},{"key":"R45-10-20210129","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.trac.2008.01.013","article-title":"HPLC methods for the determination of simvastatin and atorvastatin.","volume":"27","author":"Novakova","year":"2008","journal-title":"Trends Analyt Chem"},{"key":"R46-10-20210129","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jpba.2005.03.040","article-title":"An overview of the recent developments in analytical methodologies for determination of COX-2 inhibitors in bulk drugs, pharmaceuticals and biological matrices.","volume":"39","author":"Rao","year":"2005","journal-title":"J Pharm Biomed Anal"},{"key":"R47-10-20210129","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S1570-0232(04)00745-7","article-title":"Quantitation of tigecycline, a novel glycylcycline, by liquid chromatography.","volume":"811","author":"Li","year":"2004","journal-title":"J Chromatogr B"},{"key":"R48-10-20210129","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1128\/AAC.49.1.220-229.2005","article-title":"Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects.","volume":"49","author":"Muralidharan","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"R49-10-20210129","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ijantimicag.2005.02.013","article-title":"Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline.","volume":"25","author":"Conte Jr","year":"2005","journal-title":"Int J Antimicrob Agents"},{"key":"R50-10-20210129","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.jpba.2007.04.017","article-title":"A novel antibiotic bone assay by liquid chromatography\/tandem mass spectrometry for quantitation of tigecycline in rat bone.","volume":"44","author":"Ji","year":"2007","journal-title":"J Pharm Biomed Anal"},{"key":"R51-10-20210129","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.jpba.2008.06.020","article-title":"A sensitive human bone assay for quantitation of tigecycline using LC\/MS\/MS.","volume":"48","author":"Ji","year":"2008","journal-title":"J Pharm Biomed Anal"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0b013e3181dda54f","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:16:02Z","timestamp":1786040162000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00007691-201006000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e3181dda54f","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}